Pfizer fails to establish standing for patent challenge
28-04-2020
Novartis tries to block generic versions of Gilenya, enforces new patent
30-01-2020
II.studio / Shutterstock.com
Argentum Pharmaceuticals can’t have a Novartis patent for a multiple sclerosis drug invalidated because it doesn’t have standing to bring the challenge, the US Court of Appeals for the Federal Circuit has ruled.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Argentum Pharmaceuticals, Novartis, Gilenya, multiple sclerosis, Teva, Actavis, KVK-Tech, ANDA, FDA, US Food and Drug Administration
